Noxafil

Składnik aktywny:

posakonatsoli

Dostępny od:

Merck Sharp and Dohme B.V

Kod ATC:

J02AC04

INN (International Nazwa):

posaconazole

Grupa terapeutyczna:

Antimykoottiset aineet systeemiseen käyttöön

Dziedzina terapeutyczna:

Candidiasis; Mycoses; Coccidioidomycosis; Aspergillosis

Wskazania:

Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ja 5. 1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 ja 5. 1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Vastareaktioita on määritelty, jos infektio etenee tai epäonnistuminen parantaa jälkeen vähintään 7 päivää ennen terapeuttisia annoksia tehokasta sienilääkitystä. Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 ja 5. 1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis.  Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ja 5. 1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 ja 5. 1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Vastareaktioita on määritelty, jos infektio etenee tai epäonnistuminen parantaa jälkeen vähintään 7 päivää ennen terapeuttisia annoksia tehokasta sienilääkitystä. Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 ja 5. 1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections. Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis.  Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 ja 5. 1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Vastareaktioita on määritelty, jos infektio etenee tai epäonnistuminen parantaa jälkeen vähintään 7 päivää ennen terapeuttisia annoksia tehokasta sienilääkitystä. Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis.  Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- Invasiivinen aspergilloosi potilailla, joiden sairauteen, joka on tulenkestävä amfoterisiini B tai itrakonatsoli eivät tehonneet tai kun potilaat eivät sietäneet näitä lääkkeitä;- epäilty fusarioosi potilailla, joilla on sairaus, joka on tulenkestävä amfoterisiini B: tä tai potilailla, jotka eivät siedä amfoterisiini B;- Kromoblastomykoosi ja mysetooman hoidossa potilailla, joilla on sairaus, joka on tulenkestävä itrakonatsoli tai potilailla, jotka eivät siedä itrakonatsoli;- Koksidioidomykoosi potilailla, joilla on sairaus, joka on tulenkestävä amfoterisiini B, itrakonatsoli tai flukonatsoli, tai potilailla, jotka eivät siedä näitä lääkkeitä;- Suunielun kandidiaasi: ensilinjan lääkkeenä potilaille, joiden sairaus on vakava tai joiden immuunipuolustus on heikentynyt, ja vastaus paikalliseen hoitoon odotetaan olevan heikon. Vastareaktioita on määritelty, jos infektio etenee tai epäonnistuminen parantaa jälkeen vähintään 7 päivää ennen terapeuttisia annoksia tehokasta sienilääkitystä. Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Podsumowanie produktu:

Revision: 37

Status autoryzacji:

valtuutettu

Data autoryzacji:

2005-10-25